^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

Excerpt:
Patients with K-RAS mutated colorectal cancer, progressing on first-line oxaliplatin-based chemotherapy with bevacizumab, were eligible for this multicenter open-label phase I/II trial...All had K-RAS exon 2 mutated tumors...Three patients (9.7 %) had partial response. Sixteen patients (51.6 %) had stable disease for ≥4 weeks, including three >1 year.
DOI:
0.1007/s00280-014-2609-3